Wait goes on for effective long Covid treatments (Links to an external site)
WashU study co-author and epidemiologist, Ziyad Al-Aly, MD discusses the “staggeringly high burden” of long COVID in the past two+ years.
Institute Director led study: Anti-inflammatory drugs did not speed COVID-19 recovery but prevented deaths (Links to an external site)
The Larry J. Shapiro Director of the Institute for Public Health, William Powderly, MD, was national lead investigator of a clinical trial involving patients with severe COVID who were administered two anti-inflammatory drugs. Read more about the study’s findings.
Real-world reflections (Links to an external site)
Institute for Public Health Faculty Scholar Ziyad Al-Aly, MD, is featured in this month’s WashU’s Outlook Magazine about his work on “society’s biggest health issues through vast data analysis”
What a lifetime of long-COVID could look like for you (Links to an external site)
School of Medicine Clinical Epidemiologist and Faculty Scholar, Ziyad Al-Aly discusses how long COVID can manifest as heart problems.
Long-Covid symptoms are less common now than earlier in the pandemic (Links to an external site)
Finally some good news about long COVID. Ziyad Al-Aly, director of WashU’s Clinical Epidemiology Center says its complicated, but LC symptoms are less common now.